Eventi Capital Partners
250 Yonge Street Suite 1602, Toronto, ON, M5B 2L7, Canada
Overview
Eventi Capital Partners is a Toronto-based growth capital investment group, specializing in commercialization of rapid growth technologies. Founded in 2002, Eventi Capital Partners leverages the extensive operational and investment experience of its Managing Partners to enable CEOs to scale their business more predictably. We invest in passionate entrepreneurs who possess deep domain expertise and are committed to building a scalable company that delivers exceptional value to its customers. Historically we have invested across various stages from early revenue and transition phases to later stages of growth. As operators and serial entrepreneurs ourselves, we understand the challenges of managing high growth businesses and work closely with the CEOs and management teams to help shape the strategy and often assist in the execution.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 0
Sector focus
- E-Commerce
- Health Care
Investment portfolio
- Common Wealth
Participated · Series A · Apr 2026
Founded in 2015, Common Wealth offers a software platform that enables small and mid-sized employers to provide workplace retirement plans. Since early 2024 the company has tripled its employer base, grown membership 3.5x, and quadrupled assets under administration, and it now serves more than 1,500 organizations across Canada. It has expanded its advisor network to about 400 and launched a savings program for personal support workers with support from the Government of Canada. Management says the platform aims to help Canadians turn savings into reliable income and to open the retirement market to employees of SMEs. The company has highlighted a large market opportunity, citing research that more than nine million Canadian employees may lack access to workplace retirement plans and that fewer than one in five SMEs with five to 500 employees offer such plans. Common Wealth intends to invest in product development (including AI), distribution, and team growth as it scales.
- Base Pair Biotechnologies
Led · Series A · Nov 2017
Base Pair Biotechnologies is an aptamer discovery and development company that combines a highly customized discovery approach with a patented multiplexing technology using DNA barcoding and next-generation sequencing to identify aptamers binding up to 30 different targets. Aptamers are small synthetic RNA or DNA molecules that fold into unique shapes enabling selective and tight binding to molecular, viral, or cellular targets. The company provides custom aptamer discovery and development services, offers a small catalog of aptamers, and maintains a significant and growing intellectual property portfolio. Base Pair will use the $3.2 million Series A-3 to acquire new lab instruments and technology to expand its cellular and molecular analysis capabilities and to improve methods for finding aptamers that bind targets on and in live cells. The funding will also be used to expand the team, provide additional technical capability, and enhance geographical reach; the company has opened a new 5,000 square-foot laboratory and office facility in Pearland, Texas. Base Pair was spun out of BioTex, Inc. in 2012 and serves customers across pharma and biopharma, diagnostics, environmental testing, and veterinary medicine.
Team
No current team members are available.